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Abstract
Background: Individuals with substance use disorders (SUDs) are at increased risk for hepatitis
C viral infection (HCV), and few studies have explored their treatment responses empirically. The
objective of this study was to assess interferon alpha therapy (IFN) completion and response rates
among patients with HCV who had a history of comorbid SUDs. More data is needed to inform
treatment strategies and guidelines for these patients. Using a medical record database, information
was retrospectively collected on 307,437 veterans seen in the Veterans Integrated Service
Network 20 (VISN 20) of the Veterans Healthcare Administration (VHA) between 1998 and 2003.
For patients treated with any type of IFN (including regular or pegylated IFN) or combination
therapy (IFN and ribavirin) who had a known HCV genotype, IFN completion and response rates
were compared among patients with a history of SUD (SUD+ Group) and patients without a
history of SUD (SUD- Group).
Results: Odds ratio analyses revealed that compared with the SUD- Group, the SUD+ Group was
equally likely to complete IFN therapy if they had genotypes 2 and 3 (73.1% vs. 68.0%), and if they
had genotypes 1 and 4 (39.5% vs. 39.9%). Within the sample of all patients who began IFN therapy,
the SUD- and SUD+ groups were similarly likely to achieve an end of treatment response
(genotypes 2 and 3, 52.8% vs. 54.3%; genotypes 1 and 4, 24.5% vs. 24.8%) and a sustained viral
response (genotypes 2 and 3, 42.6% vs. 41.1%; genotypes 1 and 4: 16.0% vs. 22.3%).
Conclusion: Individuals with and without a history of SUD responded to antiviral therapy for HCV
at similar rates. Collectively, these findings suggest that patients who have co-morbid SUD and
HCV diagnoses can successfully complete a course of antiviral therapy.
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Background
Patients with co-morbid substance use disorders (SUDs)
and psychiatric disorders are at increased risk for hepatitis
C virus (HCV) infection and constitute the vast majority
of persons with chronic HCV [1-4]. HCV occurs in up to
90% of injection drug users [5]. Relative to the general
population, the incidence of HCV is also high among
non-injection drug users. In a sample of over 700 non-
injection drug users (heroin, cocaine, or crack) the preva-
lence of HCV ranged from 5% to 29%, depending on age,
gender, study location, and drugs used [6]. To date, few
studies have been completed that examine whether ongo-
ing injection or non-injection drug use affects the course
of HCV infection.
Currently, standard treatment for HCV is combination
therapy with pegylated interferon alpha (IFN) and ribavi-
rin [7,8]. However, in addition to its antiviral effects, IFN-
based therapies are also associated with a number of
adverse effects, in particular neuropsychiatric side effects
[9]. Studies suggest that as many as 75% of patients on
IFN report one or more psychiatric side effects including
depression, anxiety, insomnia, and impaired concentra-
tion [10,11], and approximately 20% – 30% meet criteria
for IFN-induced major depressive disorder [12,13].
Healthcare providers have been reluctant to treat adults
with co-morbid SUDs because of concerns that these neu-
ropsychiatric side effects may increase risk of relapse [14].
Although there is little empirical data, clinicians may also
be concerned that individuals with current or active SUDs
are more likely to be non-compliant with treatment, thus
jeopardizing efficacy [15]. Most physicians withhold anti-
viral therapy from HCV-infected alcohol or drug users
until patients have maintained abstinence for a period of
at least six months [16].
As a result of these attitudes, a disproportionately low
number of patients with SUDs have participated in clini-
cal trials or have received antiviral therapy for HCV [17].
In one prospective study of 100 patients who were
screened for psychiatric illness, SUDs, or serious medical
illness, 68 were found ineligible for IFN therapy due to the
presence of at least one of these disorders [18]. Similarly,
in another study of 557 patients referred to an HCV clinic,
21% were excluded for psychiatric disorders, 14% for cur-
rent alcohol abuse, and 3.5% for current injection drug
use [19]. One large retrospective study conducted in
France found that almost one in six patients with HCV did
not receive on-going health care following the diagnosis
of chronic HCV [20]. Close to 60% of the patients who
did not receive follow-up care belonged to the "high-risk
lifestyle group," which included patients with a history of
nasal or intravenous drug use and 22.8% of this group
were patients with current alcohol abuse (defined as > 50
g/day) [20]. These data suggest that initial barriers to treat-
ment may be related to clinician's negative attitudes about
SUDs.
There is a lack of evidence that a history of SUDs preclude
treatment tolerance or efficacy. Although sample sizes are
small, several recent studies have demonstrated adequate
viral response rates in injection drug users still actively
using [21-24]. Based on a recent review of 10 clinical trials
published between 2001 and 2004 concerning antiviral
therapy in substance users, the sustained viral response
(SVR) and adherence rates were not different from non-
drug users with HCV [25]. Other studies suggest that while
heavy drinking (> 70 to 80 g/day) has been associated
with poor SVR, individuals with a history of mild to mod-
erate alcohol use who abstain for a period prior to and
during IFN therapy have SVR rates that are similar to those
found in patients without a history of alcohol abuse [26-
30]. Less is known about mild to moderate alcohol use
during treatment, and larger sample size studies are still
needed to examine treatment compliance and response
rates in patients with HCV and co-morbid SUD.
The objective of this study was to assess antiviral therapy
completion rates as well as end of treatment response
(ETR) and SVR among patients with co-morbid SUDs
served by a large VA healthcare network in order to pro-
vide empirically based data that may facilitate treatment
decisions for this underserved patient population.
Results
HCV status, antiviral therapy and demographic 
information
Within the total sample, 3.7% (11,012/297,712) tested
positive for HCV. Of those with HCV, 7.4% (815/11,012)
received IFN therapy during the study period (1998–
2003). Patients on antiviral therapy were predominantly
male (96.0%), middle aged (49.8 +/- 5.7 years), and Cau-
casian (91.8%).
Based on SUD diagnoses, patients were categorized into
two groups: 1) SUD+ Group: 16.0% (n = 47,614), and 2)
SUD- Group: 84.0% (n = 250,098). Figure 1 includes test-
ing, infection, and treatment rates for each group. Table 1
summarizes antiviral therapy completion and response
rates for patients who initiated treatment.
HCV genotypes were not available by database or medical
record in 11.5% of treated cases, and these cases were not
included in subsequent analyses. The SUD+ and SUD-
groups did not significantly differ in terms of the percent-
age of patients with unavailable genotypes.Substance Abuse Treatment, Prevention, and Policy 2007, 2:4 http://www.substanceabusepolicy.com/content/2/1/4
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Flow diagram of all study participants Figure 1
Flow diagram of all study participants. Percentages were calculated based on the number of patients in that group divided by 
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Completion and response rate for patients with genotypes 
2 and 3
The current standard of care generally recommends for
patients with genotypes 2 and 3 to receive 24 weeks of
antiviral therapy and for patients with genotypes 1 and 4
to receive 48 weeks of antiviral therapy. Therefore, com-
pletion and response rates were analyzed by genotype. For
patients with genotypes 2 and 3, antiviral therapy comple-
tion rates were not significantly different between the
SUD+ and SUD- groups. ETRs and SVRs were unavailable
in the electronic medical record database in 6% and 4.2%
of cases respectively; the SUD+ and SUD- groups did not
differ significantly in the percentage of cases with unavail-
able ETRs (5.1% vs. 7.4%, respectively) and SVRs (4.6%
and 3.7%, respectively). Cases with unavailable ETRs and
SVRs were considered lost to follow-up and were consid-
ered non-responders in the analysis. Therefore, based on
all patients who initiated antiviral therapy (intention to
treat analysis), there were no significant differences
between the SUD+ and SUD- groups in ETR or SVR (Table
1).
Completion and response rate for patients with genotypes 
1 and 4
For patients with genotypes 1 and 4, antiviral therapy
completion rates were not significantly different between
the SUD+ and SUD- groups (Table 1). ETRs and SVRs were
unavailable in 6.4% and 1.6% of cases respectively; and
Table 1: Bivariate relationships between substance use disorders (SUD) and interferon (IFN) completion and response rates among 
veterans with available hepatitis C (HCV) genotypes
SUD- Group SUD+ Group
N % N % OR 95% CI p
Known vs. Unknown Genotype
Not available 42 12.0% 52 11.2% 1.08 0.70–1.67 0.718
Available 308 88.0% 413 88.8%
Genotypes 2 & 3
Completed ≥ 22 Weeks of IFN
No 29 26.9% 56 32.0% 0.78 0.46 – 1.33 0.359
Yes 79 73.1% 119 68.0%
End of Treatment Response (ETR)
Not available 8 7.4% 9 5.1% 1.38 0.51 – 3.74 0.528
Available 71 65.7% 110 62.9%
No Response 14 13.0% 15 8.6% 1.56 0.70 – 3.46 0.276
Response 57 52.8% 95 54.3%
Sustained Viral Response (SVR)
Not available 4 3.7% 8 4.6% 0.79 0.23 – 2.73 0.705
Available 61 56.5% 96 54.9%
No Response 15 13.9% 24 13.7% 0.98 0.47 – 2.06 0.954
Response 46 42.6% 72 41.1%
Genotypes 1 & 4
Completed ≥ 46 Weeks of IFN
No 121 60.5% 143 60.1% 1.02 0.69 – 1.49 0.929
Yes 79 39.5% 95 39.9%
End of Treatment Response (ETR)
Not available 9 8.3% 19 10.9% 0.51 0.22 – 1.21 0.124
Available 70 64.8% 76 43.4%
No Response 21 19.4% 17 9.7% 1.49 0.71 – 3.13 0.294
Response 49 45.4% 59 33.7%
Sustained Viral Response (SVR)
Not available 3 2.8% 4 2.3% 1.01 0.22 – 4.69 0.991
Available 55 50.9% 74 42.3%
No Response 23 21.3% 21 12.0% 1.81 0.87 – 3.79 0.111
Response 32 29.6% 53 30.3%
CI = Confidence interval, ETR = End of treatment response, IFN = Interferon, OR = Odds ratio, SUD = Substance use disorder, SVR = Sustained 
viral response. ORs reflect the SUD+ Group compared with the SUD- Group. The SUD+ Group includes veterans with a history of substance use 
disorder. The SUD- Group includes veterans with no history of substance use disorder. Completion rates are based on all patients with available 
genotypes. Response rates are based on all patients with known HCV genotypes who initiated IFN therapy. Patients were considered non-
responders if they failed to clear the virus or if they were lost to follow-up (e.g., unavailable ETR or SVR).Substance Abuse Treatment, Prevention, and Policy 2007, 2:4 http://www.substanceabusepolicy.com/content/2/1/4
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again groups did not significantly differ in the percentages
of unavailable ETRs (10.9% vs. 8.3%, respectively) or
SVRs (2.3% vs. 2.8%). Based on intention to treat, there
were no significant differences between the SUD+ and
SUD- groups in ETR or SVR (Table 1).
Discussion
Although patients with SUDs have been traditionally
excluded from antiviral therapy, our data challenges atti-
tudes that they may not be able to complete or respond to
antiviral therapy. There were no significant differences
between the SUD + and SUD - groups in completion of 24
weeks of antiviral therapy for genotypes 2 and 3 (73.1%%
vs. 68.0%), and in completion of 48 weeks of antiviral
therapy for genotypes 1 and 4 (39.5% vs. 39.9%). Addi-
tionally, our results indicate that individuals with SUDs
have similar ETRs and SVRs as those without SUDs.
To date, our study is the largest sample of HCV patients
with co-morbid SUDs (n = 432) that describes comple-
tion rates of antiviral therapy. Our results suggest that
individuals with a history of co-morbid SUD can success-
fully complete and respond to antiviral therapy. Further-
more, our results suggest that antiviral therapy is
warranted for HCV patients with SUDs.
Historically, patients with HCV and co-morbid SUDs have
been excluded from clinical trials. Consequently, IFN
therapy completion and response rates for these patient
groups are generally unknown. A recent national multi-
center study designed to assess the role of alcohol use on
HCV treatment outcomes found results similar to those
presented in this paper. These investigators found that
past alcohol use did not affect the ETR, SVR or discontin-
uation rates; however, recent alcohol use resulted in
higher treatment discontinuation and lower SVR [31].
Although not within the scope of this study, it is possible
that patients with co-morbid SUD may need to be more
carefully monitored during antiviral therapy in order to
avoid adverse effects associated with substance abuse
relapse. Future studies that utilize thorough medical
record review or prospective design may be able to assess
the effect of antiviral therapy on relapse relates as well as
what factors may contribute to improved treatment com-
pletion and response rates (e.g., co-management by men-
tal health or addiction specialists) among patients with
co-morbid SUDs.
Several factors limited the scope and generalizeability of
our study. First, results are based on a retrospective review
of an electronic medical record database; thus, it is unclear
to what extent missing variables, inconsistencies in clini-
cal reporting, or data entry/extraction errors may have
affected results. For example, genotypes were unavailable
for some patients, and the database lacked accessible ETR
and SVR information for many cases. Missing genotype,
ETR, and SVR data likely reflect our inability to extract this
information from the electronic record when clinicians
recorded this information in progress notes rather than in
pre-defined database fields. Therefore, a missing ETR or
SVR in the laboratory database did not necessarily indi-
cate that a patient was lost to follow-up or that they did
not respond. For this reason, response rates were calcu-
lated based only on those patients whose genotype, ETR,
and SVR were available by database and may be an under-
estimate of the actual number of patients who achieved
ETR or SVR. However, since the methodology and data-
base limitations were equivalent across groups, our con-
clusion that response rates did not significantly differ
between groups, likely remains valid.
Another limitation is the SUD diagnosis. Patients were
categorized as having a history of SUD based on inclusion
of this diagnosis in their medical records, but the accuracy
of these diagnoses could not be confirmed by database.
VISN 20 requires and reminds clinicians to complete only
a brief substance abuse screening questionnaire with all
patients annually, and it is likely that many patients with
SUDs remain undiagnosed. It is possible that clinicians
varied in their application of diagnostic criteria for SUDs
in the electronic medical records. Yet another limitation is
the electronic database extraction design, which did not
allow us to determine why patients may have discontin-
ued antiviral therapy. It is therefore unclear to what extent
important variables (e.g., patient noncompliance, side
effects or relapse) contributed to discontinuation or non-
response. Finally, our veteran sample is primarily Cauca-
sian, middle-aged, and male. Future studies could explore
to what extent such demographic variables affect comple-
tion and response rates in patients with SUDs.
Conclusion
Taken together, our results are consistent with emerging
research studies and treatment guidelines which suggest
that antiviral therapy is feasible in patients with ongoing
drug use (other than alcohol), if such patients are likely to
comply with treatment and do not have other contraindi-
cations [32-34]. This conclusion is consistent with the
policy proposed by Edlin et al. which states that; "deci-
sions about the treatment of HCV infection in patients
who use illicit drugs be based on individualized risk-ben-
efit assessments, just as they are for other patients. Patient
and physician should make decisions about treatment
together, after a thorough discussion of the need for
adherence to the treatment regimen and the risks of
adverse effects and reinfection."[35] In agreement with
this policy, the 2002 National Institutes of Health Con-
sensus Statement on the Management of Hepatitis C, the
Veterans Health Administration: Treatment Recommen-
dations for Patients with Chronic Hepatitis C, and theSubstance Abuse Treatment, Prevention, and Policy 2007, 2:4 http://www.substanceabusepolicy.com/content/2/1/4
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2004 Practice Guidelines for the Management of Hepatitis
C recommend that decisions about treatment of HCV in
people with psychiatric and SUDs, including injection
drug users, be made on a case-by-case basis and advise
that drug use itself is not an absolute contraindication to
IFN therapy for HCV [36-38].
Methods
Sample and data selection
We collected data on 307,437 patients treated between
January 1998 and December 2003 at all facilities in the
Veterans Integrated Service Network 20 (VISN 20) of the
Veterans Healthcare Administration (VHA): 8 medical
centers and 17 outpatient clinics in Alaska, Washington,
Oregon, and Idaho. Data were extracted from the VISN 20
CHIPS Data Warehouse, a collection of databases from
the electronic patient medical records of each facility. We
collected data on demographics, psychiatric and sub-
stance use diagnoses, HCV laboratory results, and pre-
scriptions. We did not collect data on non-veterans who
had records in the system (e.g., employees or family mem-
bers seen for humanitarian reasons), and so non-veterans
were not included in the total sample. The Portland Veter-
ans Affairs Medical Center Institutional Review Board
approved data access for this project.
We downloaded data from the VISN 20 data warehouse
into a local database using structured query language
(SQL) queries, where they were organized and exported to
SPSS, version 12.0 for analysis. Patients with a history of
schizophrenia or schizoaffective disorder (n = 9,725/
307,437; 3.2%), as defined by a Diagnostic and Statistical
Manual, Fourth Edition (DSM-IV) code for either disorder
in their medical record, were excluded from the total sam-
ple and subsequent analyses. Although not well sup-
ported by empirical research, it is a common clinical
concern that patients with schizophrenia or schizoaffec-
tive disorder may have reduced IFN completion and
response rates. Since these patients are generally over-rep-
resented in SUD populations, we excluded them from fur-




This group included all patients whose medical record
included a history of any SUD as defined by a DSM-IV
code for substance abuse or dependence (except nicotine
dependence).
SUD- group
This group included patients without any documented
history of SUD.
HCV status
We considered patients to have been tested for HCV if
they had at least one HCV lab result in their record
between 1994 and 2003 (electronic databases were not
reliably extracting data from medical records prior to
1994). HCV positive patients had a positive HCV anti-
body test, a detectable HCV viral load by polymerase
chain reaction (PCR), a positive HCV recombinant immu-
noblot assay (RIBA), or an identifiable HCV genotype. We
classified patients with positive antibody tests but nega-
tive RIBA or PCR confirmation as false positives.
Antiviral therapy
Antiviral therapy included all types of IFN (e.g., IFN-α2a,
IFN-α2b, IFN-αn1, IFN-alfacon1, pegylated IFN-α2a, and
pegylated IFN-α2b) or combination therapy (IFN and rib-
avirin) prescribed to patients who were HCV positive.
Patients' IFN treatment data were analyzed if records indi-
cated that they had been prescribed at least one prescrip-
tion for IFN during the study period (1998–2003).
HCV genotypes
Genotype lab results were confirmed through electronic
medical record review if unavailable in the laboratory
database.
IFN completion
For patients with genotypes 2 or 3, we considered them to
have completed IFN therapy if the period between their
first and last IFN prescription release date, plus an addi-
tional thirty days (typically the last prescription release is
for a one-month period), was greater than or equal to
twenty-two weeks. For patients with genotypes 1 and 4,
we considered them to have completed IFN therapy if the
period between their first and last IFN prescription release
date, plus thirty days, was greater than or equal to forty-six
weeks.
IFN response
We defined an end of treatment response (ETR) as a neg-
ative qualitative HCV viral load or a non-detectible quan-
titative HCV viral load within one month of IFN therapy
termination. We defined a sustained viral response (SVR)
as a negative qualitative HCV viral load or a non-detecti-
ble quantitative HCV viral load at a time point, which was
more than six months after IFN therapy termination.
Since many patients began therapy before or after the
study period (1998–2003), we reviewed lab results from
1994 through June 2006.
Statistical analyses
Odds ratio analyses were calculated to determine whether
patients receiving antiviral therapy (see section 2.2 Oper-
ational Definitions) for HCV were less likely to complete
or respond to antiviral therapy if they were in the SUD+Substance Abuse Treatment, Prevention, and Policy 2007, 2:4 http://www.substanceabusepolicy.com/content/2/1/4
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Group as compared with the SUD- Group. The database
did not allow us to determine whether patients had been
recommended six versus twelve months of IFN. However,
current standard of care is to prescribe 24 weeks of IFN to
patients with genotypes 2 and 3, while individuals with
genotypes 1 and 4 are generally prescribed 48 weeks of
IFN. Therefore, completion and response rates were ana-
lyzed separately for genotypes 2 and 3, and for genotypes
1 and 4. Patients with unknown genotypes were excluded
from these analyses. Figure 1 shows how patient groups
were selected for analyses.
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